Lou Gehrig's Disease
A controversial new drug for ALS could add months to patients' lives – if it actually works
In March, experts who advise the FDA questioned the efficacy of an experimental new drug for ALS. In September, they voted to approve it anyway.
Scientists who conducted the study say they couldn't determine exactly why the rate was higher but suggested that repetitive head impacts and traumatic brain injuries may play a role.
Lou Gehrig's disease can take months to diagnose, then rapidly incapacitate patients, leaving many families bankrupt before disability payments and Medicare kick in. A recent law aims to change that.
Scientists say new drugs are on the way for patients with ALS. The latest is a two-drug combo that appears to slow the progression of the fatal nerve disease with a modest but meaningful benefit.
The former Boston College baseball star was diagnosed with ALS when he was 27. He turned a fundraising challenge into a national story and helped raise millions for ALS research.
Fifty patients with Lou Gehrig's disease have volunteered for a study of a dietary supplement as an experimental treatment. Even a failure could help by eliminating a dead end from consideration.
A shrinking pool of grant money for medical research has led competing applicants to oversell weak scientific findings, critics say. The result: Many experimental treatments are worthless.
The ALS Association has raised more than $94 million in recent weeks via its online ice bucket challenge — compared with $2.7 million this time last year. Now what?